EuroBiotech—More articles of note

Newspapers

> Shares in GeNeuro fell 65% after its multiple sclerosis candidate failed to cut the number of cerebral Gad-enhancing lesions in a phase 2b trial. The study of the Servier-partnered antibody will continue up to the 12-month readout. But the failure of GNbAC1 to outperform placebo in terms of reducing lesions or relapses has dampened expectations. Statement (PDF)

> AbbVie pulled a phase 1 trial of ABBV-553 prior to enrollment on safety grounds. The action raises doubts about the future of the RORγT inverse agonist, which emerged from AbbVie’s work with French biotech Inventiva. Protocol

> Seattle Genetics exercised its option to co-develop tisotumab vedotin with Genmab. The Danish drugmaker is currently testing the antibody-drug conjugate in a phase 1/2 trial in patients with solid tumors. Seattle Genetics and Genmab will split all future costs and profits. Statement

Whitepaper

Overcoming Risk in Oncology Drug Development

Oncology drug development is full of potential obstacles and risks, and you must carefully plan each step. Download this whitepaper for tips on finding the fast track. Premier Research. Built for Biotech.

> Amcure received a €1.8 million grant to support the development of CD44v6 inhibitor AMC303. The German biotech is currently testing the drug in patients with metastatic epithelial tumors in a phase 1/2 trial. Release

> The FDA restated its concerns about the safety and efficacy of Kamada’s inhaled alpha-1 antitrypsin candidate. The Israeli biotech wants to run a phase 3 trial of the formulation but has yet to persuade the FDA to authorize it to proceed with the study. Statement

Suggested Articles

The public financing will enable Monopar to start a phase 3 trial of a prophylactic treatment for a side effect of chemoradiotherapy. 

The dispute centers on whether Asa Abeliovich used Alector’s confidential information in connection with his work for Prevail Therapeutics.

GSK poaches Merck KGaA's Martinez-Davis to helm pharma stateside; Bulto named Novartis U.S. pharma head; Allergan's Saunders set for huge parachute.